Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The future of keratoplasty

cell-based therapy, regenerative medicine, bioengineering keratoplasty, gene therapy

Mehta, Jodhbir S.a,b,c,d,e; Kocaba, Viridianaa; Soh, Yu Qianga,b,c

Current Opinion in Ophthalmology: July 2019 - Volume 30 - Issue 4 - p 286–291
doi: 10.1097/ICU.0000000000000573
CORNEAL AND EXTERNAL DISORDERS: Edited by Shahzad I. Mian
Buy

Purpose of review To provide an update on the state of development of novel therapeutic modalities for the treatment of corneal diseases.

Recent findings Novel corneal therapeutics may be broadly classified as cell therapy, regenerative medicine, bioengineered corneal grafts and gene therapy. Cell therapy encompasses cultivation of cells, such as corneal endothelial cells (CECs) and keratocytes to replenish the depleted native cell population. Regenerative medicine is mainly applicable to the corneal endothelium, and is dependent on the ability of native, healthy CECs to restore the corneal endothelium following trauma or descemetorhexis; this approach may be effective for the treatment of Peter's anomaly and Fuchs endothelial corneal dystrophy (FECD). Bioengineered corneal grafts are synthetic constructs designed to replace cadaveric corneal grafts; tissue-engineered endothelial-keratoplasty grafts and bioengineered stromal grafts have been experimented in animal models with favourable results. Gene therapy with antisense oligonucleotide and CRISPR endonucleases, including deactivated Cas9, may potentially be used to treat FECD and TGFBI-related corneal dystrophies.

Summary These novel therapeutic modalities may potentially supersede keratoplasty as the standard of care in the future.

aTissue Engineering and Stem Cell Group, Singapore Eye Research Institute

bSingapore National Eye Centre

cOphthalmology Academic Clinical Program

dDepartment of Clinical Sciences, Duke-NUS Graduate Medical School

eDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Correspondence to Professor Jodhbir S. Mehta, BSc (Hons), MBBS, PhD, FRCOphth, FRCS(Ed), Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751. E-mail: jodmehta@gmail.com

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.